This company has been marked as potentially delisted and may not be actively trading. Presbia (LENS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LENS vs. ATRC, TNDM, AORT, PLSE, FNA, MDXG, IART, SIBN, IRMD, and EMBCShould you be buying Presbia stock or one of its competitors? The main competitors of Presbia include AtriCure (ATRC), Tandem Diabetes Care (TNDM), Artivion (AORT), Pulse Biosciences (PLSE), Paragon 28 (FNA), MiMedx Group (MDXG), Integra LifeSciences (IART), SI-BONE (SIBN), Iradimed (IRMD), and Embecta (EMBC). These companies are all part of the "medical" sector. Presbia vs. AtriCure Tandem Diabetes Care Artivion Pulse Biosciences Paragon 28 MiMedx Group Integra LifeSciences SI-BONE Iradimed Embecta Presbia (NASDAQ:LENS) and AtriCure (NASDAQ:ATRC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Do analysts rate LENS or ATRC? AtriCure has a consensus price target of $50.67, suggesting a potential upside of 54.90%. Given AtriCure's stronger consensus rating and higher probable upside, analysts clearly believe AtriCure is more favorable than Presbia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Presbia 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AtriCure 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, LENS or ATRC? Presbia has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Which has preferable earnings and valuation, LENS or ATRC? Presbia has higher earnings, but lower revenue than AtriCure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPresbia$20K23,180.29-$8.41MN/AN/AAtriCure$480.08M3.37-$44.70M-$0.81-40.38 Does the media favor LENS or ATRC? In the previous week, AtriCure had 9 more articles in the media than Presbia. MarketBeat recorded 9 mentions for AtriCure and 0 mentions for Presbia. AtriCure's average media sentiment score of 1.38 beat Presbia's score of 0.00 indicating that AtriCure is being referred to more favorably in the news media. Company Overall Sentiment Presbia Neutral AtriCure Positive Does the MarketBeat Community prefer LENS or ATRC? AtriCure received 422 more outperform votes than Presbia when rated by MarketBeat users. Likewise, 69.81% of users gave AtriCure an outperform vote while only 68.42% of users gave Presbia an outperform vote. CompanyUnderperformOutperformPresbiaOutperform Votes15668.42% Underperform Votes7231.58% AtriCureOutperform Votes57869.81% Underperform Votes25030.19% Is LENS or ATRC more profitable? AtriCure has a net margin of -9.61% compared to Presbia's net margin of -36,604.35%. AtriCure's return on equity of -6.80% beat Presbia's return on equity.Company Net Margins Return on Equity Return on Assets Presbia-36,604.35% -414.02% -195.56% AtriCure -9.61%-6.80%-5.19% Do insiders and institutionals believe in LENS or ATRC? 16.4% of Presbia shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 74.2% of Presbia shares are owned by insiders. Comparatively, 3.5% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryAtriCure beats Presbia on 12 of the 16 factors compared between the two stocks. Get Presbia News Delivered to You Automatically Sign up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENS vs. The Competition Export to ExcelMetricPresbiaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$463.61M$4.44B$5.34B$8.31BDividend YieldN/A45.14%5.27%4.11%P/E RatioN/A29.9426.9819.59Price / Sales23,180.2969.02398.81136.58Price / CashN/A51.0838.3234.64Price / Book298.976.186.774.50Net Income-$8.41M$68.15M$3.24B$248.60M Presbia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENSPresbiaN/A$26.91+1.6%N/AN/A$463.61M$20,000.000.0024ATRCAtriCure3.5614 of 5 stars$32.40-0.9%$50.67+56.4%+41.1%$1.60B$480.08M-34.101,050News CoveragePositive NewsAnalyst UpgradeTNDMTandem Diabetes Care4.413 of 5 stars$22.73-1.5%$39.81+75.2%-59.9%$1.51B$982.95M-11.782,600News CoveragePositive NewsAnalyst ForecastAORTArtivion1.5411 of 5 stars$29.61+0.3%$31.40+6.0%+20.4%$1.26B$390.08M-1,480.501,300Insider TradePLSEPulse Biosciences0.7043 of 5 stars$17.13-0.3%N/A+48.5%$1.15B$700,000.000.00140FNAParagon 28N/A$13.11+0.1%$12.75-2.7%+67.6%$1.10B$256.18M-17.71343,000High Trading VolumeMDXGMiMedx Group3.9148 of 5 stars$7.16+1.6%$12.50+74.6%-14.5%$1.06B$352.38M13.02870Positive NewsIARTIntegra LifeSciences4.4483 of 5 stars$13.55-0.1%$18.63+37.5%-56.6%$1.05B$1.62B-150.543,720News CoverageGap DownSIBNSI-BONE3.5441 of 5 stars$19.45-1.7%$22.50+15.7%+35.6%$828.86M$176.60M-21.14350Positive NewsInsider TradeIRMDIradimed4.886 of 5 stars$54.21+0.6%$72.00+32.8%+20.6%$689.28M$75.15M36.14110Positive NewsEx-DividendEMBCEmbecta4.4305 of 5 stars$11.62-3.3%$20.33+75.0%-18.4%$679.11M$1.08B11.621,900News CoveragePositive NewsAnalyst UpgradeInsider Trade Related Companies and Tools Related Companies ATRC Competitors TNDM Competitors AORT Competitors PLSE Competitors FNA Competitors MDXG Competitors IART Competitors SIBN Competitors IRMD Competitors EMBC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENS) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Presbia PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Presbia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LENS Stock Free LENS Stock Alerts